Catalent | CTLT
Stock Price
60.91
Daily Change
1.27 2.12%
Monthly
2.56%
Yearly
52.30%
Q4 Forecast
57.75


Peers Price Chg Day Year Date
Agilent 133.89 1.78 1.35% 5.74% Nov/22
Elevance Health 402.78 -0.90 -0.22% -15.86% Nov/22
AstraZeneca 10,474.00 412.00 4.09% 2.95% Nov/22
Bristol-Myers Squibb 58.86 0.66 1.13% 18.29% Nov/22
Bruker 57.07 0.85 1.51% -13.23% Nov/22
Cigna 328.73 -1.32 -0.40% 14.20% Nov/22
Centene 60.34 -0.02 -0.02% -18.85% Nov/22
Charles River Laboratories 195.68 1.02 0.52% -0.62% Nov/22
Catalent 60.91 1.27 2.12% 52.30% Nov/22
Quest Diagnostics 163.55 -0.50 -0.30% 20.67% Nov/22
Danaher 235.96 1.01 0.43% 6.57% Nov/22
Glaxosmithkline 33.96 0.26 0.77% -5.17% Nov/22
Hologic 78.97 0.25 0.32% 10.08% Nov/22
Humana 298.03 2.12 0.72% -42.49% Nov/22
Illumina 140.14 3.15 2.30% 42.51% Nov/22
IQVIA Holdings 197.93 0.54 0.27% -6.64% Nov/22
Intuitive Surgical 547.61 -3.08 -0.56% 72.20% Nov/22
J&J 155.20 -0.32 -0.21% 1.77% Nov/22
Laboratory Of America 239.75 -0.22 -0.09% 12.70% Nov/22
Eli Lilly 747.50 -0.71 -0.09% 24.36% Nov/22
Lonza 521.40 -0.20 -0.04% 48.25% Nov/22
McKesson 623.70 -4.49 -0.71% 35.18% Nov/22
Merck 141.75 3.45 2.49% -11.93% Nov/22
Merck 99.27 -0.86 -0.86% -2.55% Nov/22
Mettler Toledo International 1,220.71 23.28 1.94% 11.63% Nov/22
Novartis 93.68 2.12 2.32% 8.61% Nov/22
Pfizer 25.66 0.56 2.23% -15.87% Nov/22
Revvity 112.26 1.13 1.02% 24.61% Nov/22
Repligen 142.58 0.82 0.58% -11.87% Nov/22
Roche Holding 254.30 3.20 1.27% 6.69% Nov/22
Supernus Pharmaceuticals 36.22 0.40 1.12% 30.15% Nov/22
Thermo Fisher Scientific 513.07 -2.88 -0.56% 4.54% Nov/22
UnitedHealth 592.74 -6.54 -1.09% 8.34% Nov/22
Waters 373.25 5.19 1.41% 33.12% Nov/22
West Pharmaceutical Services 316.72 -4.33 -1.35% -10.34% Nov/22
Dentsply International 18.78 0.15 0.78% -40.05% Nov/22

Indexes Price Day Year Date
US400 3342 54.93 1.67% 30.52% Nov/22
US500 5969 20.64 0.35% 30.93% Nov/22

Catalent traded at $60.91 this Friday November 22nd, increasing $1.27 or 2.12 percent since the previous trading session. Looking back, over the last four weeks, Catalent gained 2.56 percent. Over the last 12 months, its price rose by 52.30 percent. Looking ahead, we forecast Catalent to be priced at 57.75 by the end of this quarter and at 55.65 in one year, according to Trading Economics global macro models projections and analysts expectations.

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.